Selecta Biosciences to Present at Two Upcoming Investor Conferences in May
April 26 2017 - 8:00AM
Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage
biopharmaceutical company focused on developing biologic therapies
for rare and serious diseases that avoid unwanted immunogenicity,
today announced that President, CEO and Chairman Werner Cautreels,
Ph.D., will present at the following investor conferences in May:
- Deutsche Bank 42nd Annual Health Care Conference: Presentation
at 8:00 a.m. ET on Wednesday, May 3, 2017 in Boston.
- UBS Global Healthcare Conference: Presentation at 11:00 a.m. ET
on Tuesday, May 23, 2017 in New York City.
Live and archived webcasts of the presentations will be
available on the Investors & Media section of Selecta’s website
at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical
company focused on developing biologic therapies for rare and
serious diseases that avoid the immune responses that compromise
efficacy and lead to life-threatening complications. Selecta is
applying its proprietary Synthetic Vaccine Particles (SVP™) to a
range of therapeutic areas in which immunogenicity is a key
challenge. SEL-212, the company’s lead candidate in Phase 2, is
being developed to treat severe gout patients and reduce their
debilitating symptoms, including flares and inflammatory arthritis.
Further, Selecta’s two proprietary gene therapy product candidates
have the potential to enable repeat administration, allowing for
dose adjustment in patients and maintenance of therapeutic activity
over time. The company is seeking to expand the use of its SVP
platform in other areas, such as immuno-oncology, allergies,
autoimmune diseases and vaccines. Selecta is based in Watertown,
Massachusetts. For more information, please visit
http://selectabio.com.
Forward-Looking Statements
Any statements in this press release about the future
expectations, plans and prospects of Selecta Biosciences, Inc.
(“the company”), including without limitation, statements regarding
the development of its pipeline, the ability of the company’s SVP
platform, including SVP-Rapamycin, to mitigate immune response and
create better therapeutic outcomes, the potential treatment
applications for products utilizing the SVP platform in areas such
as gene therapy, immuno-oncology, allergies, autoimmune diseases
and vaccines, and other statements containing the words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “would,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors discussed in
the “Risk Factors” section of the company’s Annual Report on Form
10-K filed with the Securities and Exchange Commission, or SEC, on
March 28, 2017, and in other filings that the company makes with
the SEC. In addition, any forward-looking statements included in
this press release represent the company’s views only as of the
date of its publication and should not be relied upon as
representing its views as of any subsequent date. The company
specifically disclaims any obligation to update any forward-looking
statements included in this press release.
Contact Information:
Jason Fredette
Selecta Biosciences, Inc.
617-231-8078
jfredette@selectabio.com
Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Apr 2023 to Apr 2024